Great to see burn come down and again made mention of operating costs - acknowledging the issue.
I thought it was good that they made that very transparent. A number of other companies have the same issue and not mentioning the R&D rebate in the calc takes the quarterly cash above the magical 2 where you need to explain. Tick for OSL
Also no mention of the corporate sale. I assume they are taking a more practical stance on disclosure. Also good to see.
But clearly cash is the issue. Hopefully can kick some clinical, regulatory and sales goal between now and the next quarterly.
Great to see burn come down and again made mention of operating...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.015(1.48%) |
Mkt cap ! $14.65M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 95.0¢ | $109.7K | 112.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23906 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 2292 | 2 |
View Market Depth
| Last trade - 15.57pm 19/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |